UNCY News and Press, Unicycive Therapeutics Inc. From 05/01/24

2024-05-01 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the top penny stocks to buy can be rewarding. First, when it comes to penny stocks, you have to understand the high risk involved. As the U.S. Securities and Exchange Commissi...

2024-03-28 17:03:00 ET More on Unicycive Therapeutics Unicycive rises 4% on $50M private placement Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeuti...

– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – ...

2024-03-27 17:08:02 ET Developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs. ‍ Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, R...

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will...

A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...

2024-03-14 07:35:10 ET More on Unicycive Therapeutics Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeutics Read the full article on Seeking Alpha ...

LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has ent...

– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasd...

LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced enrollment has been completed in...